Association Between Secondary Prevention Medication Use and Outcomes in Frail Older Adults After Acute Myocardial Infarction
- PMID: 31002274
- PMCID: PMC6481629
- DOI: 10.1161/CIRCOUTCOMES.118.004942
Association Between Secondary Prevention Medication Use and Outcomes in Frail Older Adults After Acute Myocardial Infarction
Abstract
Background Secondary prevention medications are often not prescribed to frail, older adults following acute myocardial infarction, potentially because of the absence of data to support use, perceived lack of benefit, and concern over possible harms. We examined the effect of using more guideline-recommended medications after myocardial infarction on mortality, rehospitalization, and functional decline in the frailest and oldest segment of the US population-long-stay nursing home residents. Methods and Results We conducted a retrospective cohort study of nursing home residents aged ≥65 years using 2007 to 2010 national US Minimum Data Set clinical assessment data and Medicare claims. Exposure was the number of secondary prevention medications (antiplatelets, β-blockers, statins, and renin-angiotensin-aldosterone system inhibitors) initiated after myocardial infarction. Outcomes were 90-day death, rehospitalization, and functional decline. We compared outcomes for new users of 2 versus 1 and 3 or 4 versus 1 medications using the inverse probability of treatment-weighted odds ratios with 95% CI. The cohort comprised 4787 residents, with a total of 509 death, 820 functional decline, and 1226 rehospitalization events. Compared with individuals who initiated 1 medication, mortality odds ratios were 0.98 (95% CI, 0.79-1.22) and 0.74 (95% CI, 0.57-0.97) for users of 2 and 3 or 4 medications, respectively. Rehospitalization odds ratios were 1.00 (95% CI, 0.85-1.17) for 2 and 0.97 (95% CI, 0.8-1.17) for 3 or 4 medications. Functional decline odds ratios were 1.04 (95% CI, 0.85-1.28) for 2 and 1.12 (95% CI, 0.89-1.40) for 3 or 4 medications. In a stability analysis excluding antiplatelet drugs from the exposure definition, more medication use was associated with functional decline. Conclusions Use of more guideline-recommended medications after myocardial infarction was associated with decreased mortality in older, predominantly frail adults, but no difference in rehospitalization. Results for functional decline from the main and stability analyses were discordant and did not rule out an increased risk associated with more medication use.
Keywords: geriatrics; mortality; myocardial infarction; nursing homes; pharmacoepidemiology.
Comment in
-
More or Less Medication: Is One Better than the Other?Circ Cardiovasc Qual Outcomes. 2019 Apr;12(4):e005530. doi: 10.1161/CIRCOUTCOMES.119.005530. Circ Cardiovasc Qual Outcomes. 2019. PMID: 31002000 No abstract available.
Similar articles
-
Comparative Effectiveness of Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors in Older Nursing Home Residents After Myocardial Infarction: A Retrospective Cohort Study.Drugs Aging. 2020 Oct;37(10):755-766. doi: 10.1007/s40266-020-00791-w. Drugs Aging. 2020. PMID: 32808250 Free PMC article.
-
Association of β-Blockers With Functional Outcomes, Death, and Rehospitalization in Older Nursing Home Residents After Acute Myocardial Infarction.JAMA Intern Med. 2017 Feb 1;177(2):254-262. doi: 10.1001/jamainternmed.2016.7701. JAMA Intern Med. 2017. PMID: 27942713 Free PMC article.
-
Secondary Prevention Medication Use After Myocardial Infarction in U.S. Nursing Home Residents.J Am Geriatr Soc. 2017 Nov;65(11):2397-2404. doi: 10.1111/jgs.15144. Epub 2017 Oct 17. J Am Geriatr Soc. 2017. PMID: 29044457 Free PMC article.
-
The impact of medication adherence on clinical outcomes of coronary artery disease: A meta-analysis.Eur J Prev Cardiol. 2017 Jun;24(9):962-970. doi: 10.1177/2047487317695628. Epub 2017 Jan 1. Eur J Prev Cardiol. 2017. PMID: 28436725 Review.
-
Beta-Blockers for the Secondary Prevention of Myocardial Infarction in People with Dementia: A Systematic Review.J Alzheimers Dis. 2019;71(4):1105-1114. doi: 10.3233/JAD-190503. J Alzheimers Dis. 2019. PMID: 31476156 Free PMC article.
Cited by
-
Association of sociodemographic factors and comorbidity with non-receipt of medications for secondary prevention: a cohort study of 12,204 myocardial infarction survivors.BMC Med. 2025 Jul 1;23(1):381. doi: 10.1186/s12916-025-04160-5. BMC Med. 2025. PMID: 40597193 Free PMC article.
-
Predictors and Outcomes of Secondary Prevention Medication in Patients with Coronary Artery Disease Undergoing Percutaneous Coronary Intervention.Glob Heart. 2021 Dec 27;16(1):89. doi: 10.5334/gh.812. eCollection 2021. Glob Heart. 2021. PMID: 35141130 Free PMC article.
-
Frailty and Cardiovascular Mortality: A Narrative Review.Curr Cardiol Rep. 2023 Apr;25(4):249-259. doi: 10.1007/s11886-023-01847-0. Epub 2023 Feb 16. Curr Cardiol Rep. 2023. PMID: 36795307 Free PMC article. Review.
-
Effects of Statins for Secondary Prevention on Functioning and Other Outcomes Among Nursing Home Residents.J Am Med Dir Assoc. 2020 Apr;21(4):500-507.e8. doi: 10.1016/j.jamda.2020.01.102. Epub 2020 Mar 3. J Am Med Dir Assoc. 2020. PMID: 32144051 Free PMC article.
-
Comparative Effectiveness of Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors in Older Nursing Home Residents After Myocardial Infarction: A Retrospective Cohort Study.Drugs Aging. 2020 Oct;37(10):755-766. doi: 10.1007/s40266-020-00791-w. Drugs Aging. 2020. PMID: 32808250 Free PMC article.
References
-
- Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, de Ferranti SD, Floyd J, Fornage M, Gillespie C, Isasi CR, Jimenez MC, Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Mackey RH, Matsushita K, Mozaffarian D, Mussolino ME, Nasir K, Neumar RW, Palaniappan L, Pandey DK, Thiagarajan RR, Reeves MJ, Ritchey M, Rodriguez CJ, Roth GA, Rosamond WD, Sasson C, Towfighi A, Tsao CW, Turner MB, Virani SS, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P, American Heart Association Statistics C and Stroke Statistics S. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation 2017;135:e146–e603. - PMC - PubMed
-
- Smith SC Jr., Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, Gibbons RJ, Grundy SM, Hiratzka LF, Jones DW, Lloyd-Jones DM, Minissian M, Mosca L, Peterson ED, Sacco RL, Spertus J, Stein JH, Taubert KA, World Heart F and the Preventive Cardiovascular Nurses A. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 2011;124:2458–73. - PubMed
-
- American College of Emergency P, Society for Cardiovascular A, Interventions, O’Gara PT, Kushner FG, Ascheim DD, Casey DE Jr., Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX, Anderson JL, Jacobs AK, Halperin JL, Albert NM, Brindis RG, Creager MA, DeMets D, Guyton RA, Hochman JS, Kovacs RJ, Kushner FG, Ohman EM, Stevenson WG and Yancy CW. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology 2013;61:e78–140. - PubMed
-
- Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr., Ganiats TG, Holmes DR Jr., Jaffe AS, Jneid H, Kelly RF, Kontos MC, Levine GN, Liebson PR, Mukherjee D, Peterson ED, Sabatine MS, Smalling RW, Zieman SJ and Members AATF. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;130:e344–426. - PubMed
-
- Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr., Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH and Hawkins CM. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. The New England journal of medicine 1992;327:669–77. - PubMed